Alpha Score of 47 reflects weak overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 16, 26 | Jiang Wei | Director | BUY | 500 | $145K |
| Mar 6, 26 | Fearon Richard H | Director | BUY | 1.0K | $306K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Marshall Wace | 581K | $220.71M | NEW |
| D.E. Shaw David Shaw | 352K | $133.70M | NEW |
| Citadel Ken Griffin | 173K | $65.70M | NEW |
| Point72 Steve Cohen | 71K | $26.84M | NEW |
Waters Corporation is a leading provider of analytical instruments and software solutions for scientific research and quality control in laboratory environments worldwide. The company specializes in liquid chromatography, mass spectrometry, and thermal analysis technologies that deliver essential molecular and physical property information to support product development and quality assurance. Waters serves three primary markets: biopharmaceutical firms utilizing its instruments for drug development and regulatory compliance, industrial clients across various manufacturing sectors, and academic and government research institutions. The company's analytical instruments are considered gold standards in their applications, particularly in liquid chromatography-mass spectrometry for biopharmaceutical research. In early 2026, Waters is undergoing a significant merger with BD's life science and diagnostics business, which will expand its portfolio and market reach into diagnostics and discovery-related life science tools, fundamentally broadening the company's service offerings and customer concentrations.
Earnings calendar coming soon. Subscribe to get notified when WAT reports next.
Get earnings alerts →